A High‐Yielding Synthesis of EIDD‐2801 from Uridine**
European Journal of Organic Chemistry, 2020 An improved protocol was developed for the synthesis of EIDD‐2801, which is currently in Phase II clinical trials for the treatment of COVID‐19. The process employs uridine as starting material and proceeds through triazolation, one‐pot acetonide protection/esterification and telescoped hydroxyamination/continuous flow acetonide deprotection.
Sándor Balázs Ötvös +2 more
exaly +2 more sources
Papaverine Targets STAT Signaling: A Dual-Action Therapy Option Against SARS-CoV-2. [PDF]
J Med VirolABSTRACT Papaverine (PV) has been previously identified as a promising candidate in SARS‐CoV‐2 repurposing screens. In this study, we further investigated both its antiviral and immunomodulatory properties. PV displayed antiviral efficacy against SARS‐CoV‐2 and influenza A viruses H1N1 and H5N1 in single infection as well as in co‐infection.
Reus P +9 more
europepmc +2 more sources
In Vitro Combinatorial Activity of Direct Acting Antivirals and Monoclonal Antibodies against the Ancestral B.1 and BQ.1.1 SARS-CoV-2 Viral Variants [PDF]
VirusesCombination antiviral therapy may be helpful in the treatment of SARS-CoV-2 infection; however, no clinical trial data are available, and combined use of direct-acting antivirals (DAA) and monoclonal antibodies (mAb) has been reported only anecdotally ...
Lia Fiaschi +8 more
doaj +2 more sources
Efficacy of small molecules against the severe acute respiratory syndrome coronavirus 2 XBB1.16 and XBB1.9.2.1. [PDF]
MedComm (2020)MedComm, Volume 5, Issue 3, March 2024.
Yuan L, Liu X, Li S, Zhong W, Xia N.
europepmc +2 more sources
Antiviral activities of multiple antivirals against highly pathogenic avian influenza A H5N1 in vitro and in mice [PDF]
Emerging Microbes and InfectionsIn 2024, a bovine H5N1 strain was first isolated from dairy cows in Texas and confirmed to transmit cross-species to humans. Therefore, research on treatments for human infection should be accelerated.
Danlei Liu +8 more
doaj +2 more sources
Molnupiravir: Mechanism of action, clinical, and translational science. [PDF]
Clin Transl SciAbstract Molnupiravir is an oral prodrug of the broadly active, antiviral ribonucleoside analog N‐hydroxycytidine (NHC). The primary circulating metabolite NHC is taken up into cells and phosphorylated to NHC‐triphosphate (NHC‐TP). NHC‐TP serves as a competitive substrate for viral RNA‐dependent RNA polymerase (RdRp), which results in an accumulation ...
Maas BM +9 more
europepmc +2 more sources
Remdesivir and EIDD-1931 Interact with Human Equilibrative Nucleoside Transporters 1 and 2: Implications for Reaching SARS-CoV-2 Viral Sanctuary Sites. [PDF]
Mol Pharmacol, 2021 Equilibrative nucleoside transporters (ENTs) are present at the blood-testis barrier (BTB), where they can facilitate antiviral drug disposition to eliminate a sanctuary site for viruses detectable in semen. The purpose of this study was to investigate ENT-drug interactions with three nucleoside analogs, remdesivir, molnupiravir, and molnupiravir's ...
Miller SR +5 more
europepmc +3 more sources
Response to Comments on "Remdesivir and EIDD-1931 Interact with Human Equilibrative Nucleoside Transporters 1 and 2: Implications for Reaching SARS-CoV-2 Viral Sanctuary Sites". [PDF]
Mol Pharmacol, 2022 Miller SR +5 more
europepmc +3 more sources
Discovery, Development, and Patent Trends on Molnupiravir: A Prospective Oral Treatment for COVID-19
Molecules, 2021 The COVID-19 pandemic needs no introduction at present. Only a few treatments are available for this disease, including remdesivir and favipiravir. Accordingly, the pharmaceutical industry is striving to develop new treatments for COVID-19. Molnupiravir,
Mohd. Imran +13 more
doaj +1 more source
Antiviral activity of molnupiravir against COVID-19: a schematic review of evidences
Bulletin of the National Research Centre, 2022 Background The study was aimed at encapsulating the evidence of in vitro and in vivo antiviral activities of molnupiravir and its active form against highly pathogenic SARS-CoV-2, the pathogen responsible for COVID-19, and finding out the efficacy and ...
Shivali Singla, Sachin Goyal
doaj +1 more source